Scholarlink

Background <p>Holocarboxylase synthetase (HLCS) deficiency is an autosomal recessive organic acidaemia. This paper aimed to describe the clinical, biochemical and molecular features of four Chinese patients with HLCS deficiency, and to research the novel mutation.</p> Methods <p>Tandem mass spectrometric analysis of elevated 3-hydroxyisovaleryl carnitine (C5OH) on dried blood spots was performed. Next-generation sequencing was then used to make a definite diagnosis, and the related variants were checked in several databases.</p> Results <p>The four patients exhibited varying degrees of clinical symptoms, abnormal biochemical analysis and acylcarnitine profile. A total of six mutations in the <i>HLCS</i> gene were identified, including one novel missense mutation [c.1505&#xa0;A &gt; G (p.Gln502Arg)], and one frameshift mutation [c.2159delT (p.Leu720Profs*31)]. The variation c.1505&#xa0;A &gt; G (p.Gln502Arg) is predicted to be possibly damaging by several in silico prediction programs. Another frameshift variation, c.2159delT (p.Leu720Profs*31), is classified as uncertain significance.</p> Conclusions <p>A novel variation c.1505&#xa0;A &gt; G (p.Gln502Arg) expands the mutational spectrum of the <i>HLCS</i> gene. Patient 4 is the first patient diagnosed as HLCS deficiency carrying the c.2159delT (p.Leu720Profs*31) variation. The results may contribute to a better understanding of the clinical course and genetic characteristics of patients with HLCS deficiency.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and genetic analysis of four Chinese patients with holocarboxylase synthetase deficiency and metabolic acidosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月30日

查看全文
  • Zhenzhu Zheng,
  • Weilin Peng,
  • Yiming Lin,
  • Weihua Lin,
  • Gaoxiong Wang

摘要

Background

Holocarboxylase synthetase (HLCS) deficiency is an autosomal recessive organic acidaemia. This paper aimed to describe the clinical, biochemical and molecular features of four Chinese patients with HLCS deficiency, and to research the novel mutation.

Methods

Tandem mass spectrometric analysis of elevated 3-hydroxyisovaleryl carnitine (C5OH) on dried blood spots was performed. Next-generation sequencing was then used to make a definite diagnosis, and the related variants were checked in several databases.

Results

The four patients exhibited varying degrees of clinical symptoms, abnormal biochemical analysis and acylcarnitine profile. A total of six mutations in the HLCS gene were identified, including one novel missense mutation [c.1505 A > G (p.Gln502Arg)], and one frameshift mutation [c.2159delT (p.Leu720Profs*31)]. The variation c.1505 A > G (p.Gln502Arg) is predicted to be possibly damaging by several in silico prediction programs. Another frameshift variation, c.2159delT (p.Leu720Profs*31), is classified as uncertain significance.

Conclusions

A novel variation c.1505 A > G (p.Gln502Arg) expands the mutational spectrum of the HLCS gene. Patient 4 is the first patient diagnosed as HLCS deficiency carrying the c.2159delT (p.Leu720Profs*31) variation. The results may contribute to a better understanding of the clinical course and genetic characteristics of patients with HLCS deficiency.